Queenie Ho Yan Wong1,2, Tracy Wing Yee Yeung3, Sofie Shuk Fei Yung4, Jennifer Ka Yee Ko4, Hang Wun Raymond Li4, Ernest Hung Yu Ng4. 1. Department of Obstetrics and Gynaecology, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong. queeniehoyan@gmail.com. 2. Department of Obstetrics and Gynaecology, Princess Margaret Hospital, Kwai Chung, Hong Kong. queeniehoyan@gmail.com. 3. Hong Kong Reproductive Health Service, Central, Hong Kong. 4. Department of Obstetrics and Gynaecology, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong.
Abstract
PURPOSE: To evaluate the effect of 12-month DHEA supplementation on menstrual pattern and ovarian reserve markers in women with premature ovarian insufficiency (POI) METHODS: This is a prospective observational study. Women with POI were given DHEA supplements (25 mg three times daily) for 12 months. Sonographic assessment for ovarian volume and antral follicle count (AFC) and serum measurement for anti-Mullerian hormone (AMH), follicle stimulating hormone (FSH), estradiol, testosterone, liver function, and hemoglobin level were performed at baseline and monthly for 13 months after the supplementation. Menstrual pattern, ovarian reserve markers, and side-effects were recorded. RESULTS: Between August 2011 and July 2014, 38 women with POI were recruited and 31 completed the study. The median age of women was 36 years, and the median baseline FSH and AMH concentrations were 82.2 IU/L and 0.01 ng/ml, respectively. No women had resumption of regular menstruation after DHEA supplementation. AMH, FSH, and AFC did not change significantly. No serious side effects were reported. CONCLUSIONS: Our results do not support any significant improvement in ovarian function by 12-month DHEA supplementation in women with POI.
PURPOSE: To evaluate the effect of 12-month DHEA supplementation on menstrual pattern and ovarian reserve markers in women with premature ovarian insufficiency (POI) METHODS: This is a prospective observational study. Women with POI were given DHEA supplements (25 mg three times daily) for 12 months. Sonographic assessment for ovarian volume and antral follicle count (AFC) and serum measurement for anti-Mullerian hormone (AMH), follicle stimulating hormone (FSH), estradiol, testosterone, liver function, and hemoglobin level were performed at baseline and monthly for 13 months after the supplementation. Menstrual pattern, ovarian reserve markers, and side-effects were recorded. RESULTS: Between August 2011 and July 2014, 38 women with POI were recruited and 31 completed the study. The median age of women was 36 years, and the median baseline FSH and AMH concentrations were 82.2 IU/L and 0.01 ng/ml, respectively. No women had resumption of regular menstruation after DHEA supplementation. AMH, FSH, and AFC did not change significantly. No serious side effects were reported. CONCLUSIONS: Our results do not support any significant improvement in ovarian function by 12-month DHEA supplementation in women with POI.
Authors: Tracy Wing Yee Yeung; Raymond Hang Wun Li; Vivian Chi Yan Lee; Pak Chung Ho; Ernest Hung Yu Ng Journal: J Clin Endocrinol Metab Date: 2012-11-08 Impact factor: 5.958
Authors: Tracy Wing Yee Yeung; Joyce Chai; Raymond Hang Wun Li; Vivian Chi Yan Lee; Pak Chung Ho; Ernest Hung Yu Ng Journal: Fertil Steril Date: 2014-05-03 Impact factor: 7.329
Authors: A Narkwichean; K Jayaprakasan; W E Maalouf; J H Hernandez-Medrano; C Pincott-Allen; B K Campbell Journal: Hum Reprod Date: 2013-11-20 Impact factor: 6.918